Sept 1 (Reuters) - AstraZeneca and China's Hutchmed said on Tuesday that a late-stage trial of a combination of their cancer ...

AstraZeneca Plc AZN announced major progress across its oncology portfolio on Tuesday, highlighting positive Phase 3 trial ...

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for ...

AstraZeneca detailed the surprise failure of a closely watched heart disease trial, a study with ripple effects for a ...

AstraZeneca (AZN) and Hutchmed (HCM) announced on Tuesday that their jointly developed tyrosine kinase inhibitor Orpathys, as a first-line therapy in combination with Astra’s (AZN) TKI, Tagrisso, ...

The CREW Study from AstraZeneca focuses on patients in Japan with chronic rhinosinusitis with nasal polyps who start on Tezepelumab as part of routine care. It tracks how these patients feel and ...

Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock ...

AstraZeneca (LSE:AZN) reported positive high level results across several late stage oncology and immunology trials, ...

AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

AstraZeneca said ​on ‌Tuesday that a Chinese ‌late-stage ​trial ⁠of a ⁠combination of its cancer ​drugs Tagrisso ⁠and ...